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Table 1. Body mass index and data of ultrasound densitometry
Data/Groups Control group OA (I stage) OA (II-III stage)
60-69 years
Body mass index, un. 28,8±0,4 31,1±0,8 c 32,8±1,2 c
SOS, m/sec. 1526,7±3,3 1522,8±5,1 1511,9±5,2
BUA, dB/MG 104,4±1,1 109,6±1,6 b 102,7±1,7 e
Stiffness index, % 77,0±1,4 79,3±2,3 71,7±2,5 d
Z-range, SD 0,1±0,1 0,3±0,2 -0,3±0,2 d
70-74 years
Body mass index, un. 28,9±0,7 30,8±1,0 33,9±0,9 a
SOS, m/sec. 1514,2±4,8 1510,7±4,3 1515,5±3,9
BUA, dB/MG 101,7±2,1 105,3±1,5 106,3±1,6
Stiffness index, % 71,6±2,5 73,0±2,0 75,1±1,9
Z-range, SD 0,02±0,23 0,14±0,18 0,30±0,18
Table 2. Body mass index (is standardized) and data of ultrasound densitometry
Data/Groups Control group OA (I stage) OA (II-III stage)
60-69 years
Body mass index, un 31,6±0,4 31,4±0,7 32,8±1,2
SOS, m/sec. 1533,6±4,6 1523,2±5,2 1511,9±5,2 a
BUA, dB/MG 106,5±1,6 109,7±1,6 102,7±1,7 c
Stiffness index, % 80,3±1,9 79,5±2,3 71,7±2,5a,b
Z-range, SD 0,4±0,2 0,3±0,2 -0,3±0,2 a,b
70-74 years
Body mass index, un. 32,5±0,7 31,4±1,0 32,54±0,7
SOS, m/sec. 1516,2±7,0 1509,5±4,5 1515,0±4,0
BUA, dB/MG 100,1±3,1 105,4±1,6 106,1±1,7
Stiffness index, % 71,0±3,8 72,8±2,1 74,9±1,9
Z-range, SD -0,03±0,34 0,11±0,20 0,27±0,18
worse in compared with other groups (Table 2). The obtained
results conﬁrm that the indices of structural-functional state of
bone mass of patients with OA progression become worse.
Conclusions: The higher indices of ultrasound densitometry
have been established in the patients, aged 60-69 years, with
the initial stage of knee OA (1st stage) as compared with the
2d and 3d ones and women of control group. The data of bone
state in women, aged 70-74 years is not differ in depend of
presence of OA. Obesity is protecting factor from bone loss only
for women with knee OA, aged 60-69 years, not for women, aged
70-74 years.
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THE UTILITY OF SYNOVIAL FLUID REPLACEMENT IN
ARTHROSCOPIC SHOULDER SURGERY IN THE
PREVENTION OF POST-OPERATIVE PAIN
D. Cohen, M. Waseem
Macclesﬁeld District General Hospital, Manchester, United
Kingdom
Purpose: Post operative pain following arthroscopic procedures
is a well recognised problem.
Using a prospective randomised control trial, we compared the
effectiveness of Viscoseal®, an exogenous hyaluronan (Image
Image 1
1), with diamorphine which at the time was used in our depart-
ment, as a subacromial analgesic injection following shoulder
arthroscopy.
Methods: Twenty adult patients undergoing arthroscopic sub-
acromial decompression were randomised into two groups. The
Viscoseal group received 10ml of Viscoseal® and 10ml of 0.5%
bupivacaine injected into the subacromial bursa at completion
of the procedure (n=10) (Image 2). The matched control group
received 10mg diamorphine and 10mls of 0.5% bupivacaine
(n=10).
Image 2
All procedures were performed by the senior author. The patients
were blinded to the injections given. Post-operative regimes were
standardised and all patients were assessed by visual analogue
pain scores at recovery and 1, 2, 6, 12 & 24 hours post-operative.
The presence or absence of nausea and time to discharge were
also noted.
Differences in postoperative data were tested by Students t-test
or Fisher exact tests as appropriate. P-values of 0.05 or less
deﬁned signiﬁcance.
Results: The mean age of the Viscoseal® group was 53 (range
34-70) years and the control group 59 (32-85) years.
40% of patients receiving Viscoseal® were able to be discharged
on the day of operation compared with none in the diamorphine
group because of nausea and vomiting, however this difference
did not reach statistical signiﬁcance (P=0.054).
There were no signiﬁcant differences in post-operative pain
scores (Image 3) or in the quantity of supplementary analgesic
drug doses given post operatively.
The incidence of PONV was much higher (present in 60% vs
10%) in the group receiving intra-articular diamorphine (P=0.03).
Image 3
Conclusions: Arthroscopic surgery has never been more popu-
lar. One of the many beneﬁts of this type of surgery is that it can
often be performed as a day-case. However, good post-operative
analgesia is essential if this is to be achieved.
Evidence exists to suggest that Viscoseal® may reduce the
pain after arthroscopic knee and shoulder surgery, this study
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demonstrates an analgesic effect as good as diamorphine and
bupivacaine. Not surprisingly, the intra-articular injection of opiate
was associated with a signiﬁcant incidence of post operative
nausea and vomiting.
The limitation in the study was the small number of patients and
a larger group may well have shown statistical signiﬁcance in
time to discharge. If this were the case the difference in price of
bupivacaine and diamorphine (£3.78) compared to Viscoseal®
(£52.88) is small compared to the cost of an overnight stay
(£180-NHS & £400-PS). Viscoseal® was well tolerated and safe
and no adverse reactions occurred during the study.
We do recommend the use of Viscoseal® as an analgesic intra-
articular injection following arthroscopic shoulder surgery.
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PATIENTS’ PERCEPTIONS OF THE EFFECT OF
HYALURONIC ACID (EUFLEXXA) ON KNEE PAIN
INDUCED DIFFICULTIES WITH ACTIVITIES OF DAILY
LIVING AND SOCIAL OR LEISURE ACTIVITIES
E. Onel1, D.L. Kerney2, M.R. Rogers3
1Ferring Pharmaceuticals, Parsippany, NJ; 2InfoMedics, Inc.,
Woburn, MA; 3West Houston Orthopedic and Sports Medicine
Center, Houston, UT
Purpose: To ascertain patients’ perceptions of the level of re-
lief obtained with Euﬂexxa (hyaluronic acid) for pain due to
osteoarthritis in the knee as it pertains to their activities of
daily living (ADLs) and their leisure or social activities after 3
months and after 6 months, and to report that information back
to physicians. The ability of patients to take care of themselves
is reﬂected in their ADLs; depression is related to social and
leisure activities.
Methods: 1,261 US physicians participated in this ongoing
prospective study by identifying patients eligible for treatment
with Euﬂexxa and providing them with survey materials. Patients
wishing to participate voluntarily telephoned a study coordina-
tor, provided consent, and used an automated interactive voice
response system to complete surveys about their condition at
baseline (before treatment with Euﬂexxa), after three months,
and after six months; of 518 patients enrolled, 161 (31%) com-
pleted all three surveys (mean age 65; 67% female). The survey
content included questions on patient ADLs and social or leisure
activities, as well as demographic information and other clinical
questions. After a patient completed each follow-up survey, the
physician received a one-page summary.
Results: Patients receiving Euﬂexxa reported a decrease in the
amount that their knee pain interfered with their ADLs, with a
mean baseline score of 5.8 (range of 0=doesn’t interfere at all
to 10=interferes very much) decreasing to 3.7 at 3 months and
maintaining at 3.9 at 6 months. Patients receiving Euﬂexxa also
reported a decrease in the amount that their knee pain interfered
with their social and leisure activities, with a mean baseline
score of 5.6 (range of 0 to 10) decreasing to 3.6 at 3 months and
maintaining at 3.7 at 6 months.
Conclusions: Based on patients’ perceptions, Euﬂexxa is effec-
tive for reducing the amount that knee pain interferes with their
ADLs, allowing this population to better care for itself even as
it ages. Euﬂexxa is also effective at reducing the amount that
knee pain interferes with social and leisure activities, allowing
this population greater interactions and potentially decreasing
the risk for depression. Through surveys such as this, patients
can communicate to physicians their impressions of the impact
of the medication on their condition. Physicians can then view
this subjective information in conjunction with objective, clinical
evaluations in an effort to optimize a patient’s treatment and
achieve the best possible outcome.
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A STANDARDISED HERBAL REMEDY MADE FROM
ROSA CANINA REDUCES PAIN IN PATIENTS SUFFERING
FROM OSTEOARTHRITIS
K. Winther1, A. Kharazmi2
1Frederiksberg Hospital, University of Copenhagen,
Copenhagen, Denmark; 2Rigshospitalet, University of
Copenhagen, Copenhagen, Denmark
Purpose: In clinical trials on osteoarthritis, i-ﬂex™/LitoZin™,
a standardised rose hip powder produced by HybenVital, has
shown anti-inﬂammatory and cell preserving capacity and a re-
duction in symptom score using WOMAC. This study aimed to
investigate if a change in symptom score (primary effect variable:
pain) could be detected using daily evaluation.
Methods: This randomized, double-blind, cross-over study in-
cluded patients with at least light to moderate pain from os-
teoarthritis. The patients were treated with either placebo or rose
hip powder (5g daily) for a period of 3 months, after which the
placebo group was changed to active treatment and vice versa.
On inclusion and after 3 months of each treatment period pain
was estimated on a 10 step categorical scale (10 indicating the
worst pain experienced). Additionally, on a daily basis throughout
the whole 6 months study period the following parameters were
evaluated: pain, stiffness, general wellbeing, quality of sleep and
mood, using similar scales as for pain.
Results: Categorical pain scales were available from 67 patients
and daily evaluation from 47 patients. In the former group of
67 patients, active treatment tended to be superior to placebo
although not signiﬁcantly (p<0.067). As a strong carry-over ef-
fect was detected, a Mann-Whitney test comparing the two
groups after only 3 months treatment was applied. This analysis
demonstrated signiﬁcant effects of active treatment (p<0.042).
Pain, when evaluated on the day by day basis in all the avail-
able patients, was in favour of active treatment (p<0.020). A
Mann-Whitney test applied after 3 months treatment supported
these ﬁndings (p<0.036). An identical pattern was observed for
stiffness, wellbeing, sleeping quality and mood, which all signiﬁ-
cantly improved as a result of active therapy, irrespective of the
statistical methodology used.
Conclusions: These data suggest that the present rose hip
powder reduces symptoms of osteoarthritis and that a daily eval-
uation of symptom score can result in a more detailed evaluation,
especially regarding the onset and time course of symptom relief.
Pain: Pathophysiology
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ANALGESIC EFFECT OF NEUROTROPIN ON CHRONIC
PAIN OF MONO-IODOACETATE-INDUCED
OSTEOARTHRITIS RATS
M. Naiki, T. Numazawa, K. Sawada, T. Okada, N. Taguchi,
H. Namba, M. Kawamura
Department of Development Research, Instutute of Bio-Active
Science, Nippon Zoki Pharmaceutical CO., LTD., Hyogo, Japan
Purpose: Neurotropin is a non-protein extract from the inﬂamed
skin of rabbits inoculated with vaccinia virus and has been
widely used to treat chronic pain of diseases such as lumbago,
neck-shoulder-arm syndrome, osteoarthritis (OA), post-herpetic
neuralgia (PHN),and subacute myelo-optico-neuropathy (SMON)
in Japan. In this study, the analgesic effect of Neurotropin was
compared with NSAIDs using mono-iodoacetate (MIA)-induced
OA model, and the action mechanism of analgesic effect of
Neurotropin was examined.
